IL151235A0 - Novel crystal forms of 9-substituted hypoxanthine derivatives - Google Patents

Novel crystal forms of 9-substituted hypoxanthine derivatives

Info

Publication number
IL151235A0
IL151235A0 IL15123501A IL15123501A IL151235A0 IL 151235 A0 IL151235 A0 IL 151235A0 IL 15123501 A IL15123501 A IL 15123501A IL 15123501 A IL15123501 A IL 15123501A IL 151235 A0 IL151235 A0 IL 151235A0
Authority
IL
Israel
Prior art keywords
crystal forms
novel crystal
substituted hypoxanthine
hypoxanthine derivatives
derivatives
Prior art date
Application number
IL15123501A
Other languages
English (en)
Original Assignee
Neotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotherapeutics Inc filed Critical Neotherapeutics Inc
Publication of IL151235A0 publication Critical patent/IL151235A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL15123501A 2001-02-21 2001-02-16 Novel crystal forms of 9-substituted hypoxanthine derivatives IL151235A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/005462 WO2003011863A1 (fr) 2001-02-21 2001-02-21 Formes cristallines de derives d'hypoxanthine substitues en 9

Publications (1)

Publication Number Publication Date
IL151235A0 true IL151235A0 (en) 2003-06-24

Family

ID=21742354

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15123501A IL151235A0 (en) 2001-02-21 2001-02-16 Novel crystal forms of 9-substituted hypoxanthine derivatives

Country Status (8)

Country Link
US (1) US6407237B1 (fr)
EP (1) EP1368350A1 (fr)
JP (1) JP2004521956A (fr)
CN (1) CN1232521C (fr)
CA (1) CA2417337A1 (fr)
IL (1) IL151235A0 (fr)
MX (1) MXPA02007997A (fr)
WO (1) WO2003011863A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637449B2 (en) * 2009-08-27 2014-01-28 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3300380A (en) 1963-12-26 1967-01-24 Upjohn Co Diminishing toxicity of antiviral nu6-(hydroxyalkyl) adenines with 4-hydroxypyrazolo(3, 4-d) pyrimidine
US3321369A (en) 1965-05-26 1967-05-23 Abbott Lab Method of enhancing learning rate and retention level in warm blooded animals
US3438968A (en) 1966-06-23 1969-04-15 Int Chem & Nuclear Corp Substituted ammonium basic addition salts of ribonucleic acid
BE759011A (fr) 1969-11-17 1971-05-17 Wellcome Found Aminopurines
DE2554453A1 (de) 1974-12-18 1976-06-24 Experimentales Et Cliniques De Medikament zur glykaemieregulierung
GB1530912A (en) 1975-02-13 1978-11-01 Wellcome Found Compositions containing 9-(2-hydroxy-3-alkyl)-adenines
US4138562A (en) 1977-02-09 1979-02-06 The Regents Of The University Of Minnesota Adenosine deaminase resistant antiviral purine nucleosides and method of preparation
US4221910A (en) 1978-09-15 1980-09-09 Newport Pharmaceuticals International, Inc. 9-(Hydroxy alkyl)purines
US4221909A (en) 1978-09-15 1980-09-09 Sloan-Kettering Institute For Cancer Research P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines
US4221794A (en) 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4340726A (en) 1980-03-14 1982-07-20 Newport Pharmaceuticals International, Inc. Esters
US4347360A (en) 1980-09-16 1982-08-31 Ens Bio Logicals Inc. Ring open nucleoside analogues
US4451478A (en) 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US5093318A (en) 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US4952693A (en) 1984-10-12 1990-08-28 Warner-Lambert Company Oxazolo-pyrimidine derivatives
US5495010A (en) 1987-04-17 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services Acid stable purine dideoxynucleosides
EP0691348A1 (fr) 1988-04-19 1996-01-10 Institut Pasteur Composition immunogéniques préparés à partir de l'adénylate-cyclose de B.parapertussis
IT1227389B (it) 1988-07-07 1991-04-08 Mini Ricerca Scient Tecnolog Dispersioni acquose di polimeri uretano-acrilici e loro impiego come vernici.
US5256677A (en) 1989-05-23 1993-10-26 Abbott Laboratories Retroviral protease inhibiting compounds
US5187162A (en) 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5091432A (en) 1990-03-28 1992-02-25 Glasky Alvin J 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5801184A (en) 1994-07-25 1998-09-01 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5447939A (en) 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5795756A (en) 1995-12-11 1998-08-18 Johnson; Roger A. Method and compounds for the inhibition of adenylyl cyclase
US5948771A (en) 1996-01-31 1999-09-07 The Trustees Of Columbia University In The City Of New York Method for treating heart failure using tetrapyrroles and metallotetrapyrroles
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
AU3879899A (en) 1998-05-04 1999-11-23 Neotherapeutics, Inc. Novel dopamine-like 9-substituted hypoxanthine and methods of use
AU3785799A (en) 1998-05-04 1999-11-23 Neotherapeutics, Inc. Method for treating migraine in mammals
US6303617B1 (en) 1998-05-04 2001-10-16 Neotherapeutics, Inc. Serotonin-like 9-substituted hypoxanthine and methods of use

Also Published As

Publication number Publication date
CN1232521C (zh) 2005-12-21
WO2003011863A1 (fr) 2003-02-13
EP1368350A1 (fr) 2003-12-10
JP2004521956A (ja) 2004-07-22
MXPA02007997A (es) 2005-07-01
CA2417337A1 (fr) 2003-02-13
CN1427841A (zh) 2003-07-02
US6407237B1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
HK1208446A1 (en) Derivatives of uk-2a uk-2a
PT1644384E (pt) Processo e intermediários para a síntese de entecavir
AU2003248651A8 (en) Optical metrology of single features
KR100908796B9 (ko) 아세트산아닐리드 유도체의 α형 또는 β형 결정
HK1066215A1 (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
IL160721A0 (en) Crystalline forms of valacyclovir hydrochloride
EP1415974A4 (fr) Procede de production de derives fluores du norbornene
IL172006A0 (en) Novel crystalline forms of valacyclovir hydrochloride
GB2383038B (en) Anhydrous crystal form of valaciclovir hydrochloride
AU2003232719A1 (en) Novel crystalline forms of valacyclovir hydrochloride
IL166592A0 (en) Novel crystalline forms of gatifloxacin
IL148825A0 (en) Derivatives of isoflavones
AU2002230164A1 (en) Crystal of pyrimidine nucleoside derivative
IL165115A0 (en) Novel crystalline forms of gatifloxacin
AU2003289995A1 (en) Anhydrous crystalline form of valacyclovir hydrochloride
PL373845A1 (en) Crystal forms of olanzapine and processes for their preparation
AU2003216848A1 (en) Deracemisation of amines
IL151235A0 (en) Novel crystal forms of 9-substituted hypoxanthine derivatives
GB0207623D0 (en) Crystal structure of g-quadruplex
IL164712A0 (en) Antiviral inhibition of capsid proteins
HUP0400869A3 (en) Novel crystal forms of phenylethenesulfonamide pyrimidin derivative and process for producing the same
EP1288215B8 (fr) Procédé de préparation de Famciclovir et prodédé de préparation et cristallisation d' un intermediaire correspondant
IL165690A0 (en) Novel crystalline forms of gatifloxacin
PL373972A1 (en) Process for the preparation of morpholine derivatives and intermediates therefore
EP1486485A4 (fr) Nouveaux cristaux de derive de 5-hydroxycarbamimidoyl-2-hydroxybenzenesulfonamide